Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    MK8591A-028
Previous Study | Return to List | Next Study

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04295772
Recruitment Status : Active, not recruiting
First Posted : March 4, 2020
Last Update Posted : December 22, 2021
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 29, 2022
Estimated Study Completion Date : January 26, 2024